Cardiogenic shock

7 trials 3 recruiting MedDRA PT
7 Registered trials
3 Recruiting
6 Unique sponsors
9 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
A Gastroenterology (ATC A) 2
B Haematology (ATC B) 2
N Neurology/Psychiatry (ATC N) 1
C Cardiology (ATC C) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 7 substances
Supportive / diluent 1 substance
SGLT2 inhibitor 1 substance
Phase III: 3 Phase II: 2 Phase I/II: 1 Phase IV: 1

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase III

3 trials
  • Assistance Publique Hopitaux De Paris Academic
    ISOFLURANE
    2023-510261-94-00 1 country 2026 n=300
    Recruiting
  • CHRU De Nancy Academic
    EMPAGLIFLOZIN
    2023-503602-37-00 1 country 2024 n=164
    Recruiting
  • CHRU De Nancy Academic
    LEVOSIMENDAN; PANTOTHENATE SODIUM, RIBOFLAVIN SODIUM PHOSPHATE, BIOTIN, CYANOCOBALAMIN, FOLIC ACID, NICOTINAMIDE, SODIUM ASCORBATE, THIAMINE NITRATE, PYRIDOXINE HYDROCHLORIDE; RETINOL PALMITATE, ASCORBIC ACID, BIOTIN, COLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NICOTINAMIDE, PYRIDOXINE HYDROCHLORIDE, DL-ALPHA-TOCOPHEROL, COCARBOXYLASE TETRAHYDRATE
    2024-513811-29-00 1 country 2023 n=506
    Recruiting

Phase II

2 trials
  • Windtree Therapeutics Inc. Commercial
    ISTAROXIME
    2023-507243-11-02 3 countries 2025 n=80
    Ended
  • Oslo Universitetssykehus HF Academic
    GLUCOSE; INSULIN LISPRO; POTASSIUM CHLORIDE PH. EUR.
    2025-523858-13-01 1 country n=20
    Pending

Phase I/II

1 trial
  • 4TEEN4 Pharmaceuticals GmbH Commercial
    IMP not specified
    2024-518450-16-00 5 countries 2025 n=101
    Halted

Phase IV

1 trial
  • Azienda Unita' Sanitaria Locale Toscana Sud Est Academic
    IMP not specified
    2024-520399-84-00 1 country 2025 n=46
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
CHRU De Nancy Academic 2 Phase III 2
Windtree Therapeutics Inc. Commercial 1 Phase II 0
4TEEN4 Pharmaceuticals GmbH Commercial 1 Phase I/II 0
Oslo Universitetssykehus HF Academic 1 Phase II 0
Assistance Publique Hopitaux De Paris Academic 1 Phase III 1
Azienda Unita' Sanitaria Locale Toscana Sud Est Academic 1 Phase IV 0
New trials by year
2023
1
2024
1
2025
3
2026
1
← All indication landscapes